coreceptor

(redirected from Co-receptor)
Also found in: Wikipedia.

co·re·cep·tor

(kō'rē-sep'tōr),
A cell surface receptor, which, when bound to its respective ligand, modulates antigen receptor binding or affects cellular activation after antigen-receptor interactions.

co·re·cep·tor

(kō'rĕ-sep'tŏr)
A cell surface protein that increases the sensitivity of the antigen receptor to antigen by binding to other ligands.

coreceptor

(ko?re-sep'tor) [ com- + receptor]
A structure on a cell membrane that enhances the action of the cell receptor.

CCR5 coreceptor

A cell surface receptor found on macrophages that facilitates entry of HIV-1 into these cells. Chemokines released by T cells attempt to compete with HIV by blocking the receptor to prevent infection.

CXCR4 coreceptor

A cell surface receptor found on T cells that facilitates entry of HIV-1into these cells.
Synonym: fusin
References in periodicals archive ?
mice develop moderate lupus-like disease, (22) CD72 appears to be a major inhibitory co-receptor that activates SHP-1 to prevent autoimmunity.
The new study builds on previous discoveries by the Farzan laboratory, which show that a co-receptor called CCR5 contains unusual modifications in its critical HIV-binding region, and that proteins based on this region can be used to prevent infection.
INTRODUCTION: HIV most commonly uses CCR5 as a co-receptor to enter its target cells.
JAM proteins serve as a sort of co-receptor for Notch signaling in that they are required to maintain close contact between signal-emitting and signal-receiving cells to permit strong activation of Notch in the precursors of HSCs.
Another co-receptor expressed by T cells is Cytotoxic T Lymphocyte Antigen-4 (CTLA-4), which interacts with the same ligand on the APC.
Although the HIV virus was initially discovered to infect cells via a receptor called CD4, researchers found in 1996 that HIV infection requires a co-receptor, usually CCR5.
What's more, blocking the receptor with the CCR5 antagonists Maraviroc and Vicriviroc, two drugs that slow down the spread of the HIV virus by targeting the CCR5 co-receptor of the chemokine CCL5, also prevents migration and spread of breast cancer cells, the researchers found.
Since certain antirctroviral drugs act by blocking HIV entry through co-receptor activation, additional resistance tests are necessary to determine the efficacy of those drugs.